Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

72.89B

Market cap72.89B

Price-Earnings ratio

16.54

Price-Earnings ratio16.54

Dividend yield

0.54%

Dividend yield0.54%

Average volume

735.00K

Average volume735.00K

High today

$696.74

High today$696.74

Low today

$660.02

Low today$660.02

Open price

$676.93

Open price$676.93

Volume

900.13K

Volume900.13K

52 Week high

$821.11

52 Week high$821.11

52 Week low

$541.00

52 Week low$541.00

Stock Snapshot

The current Regeneron(REGN) stock price is $690.00, with a market capitalization of 72.89B. The stock trades at a price-to-earnings (P/E) ratio of 16.54 and offers a dividend yield of 0.54%.

On 2026-07-28, Regeneron(REGN) stock moved within a range of $660.02 to $696.74. With shares now at $690.00, the stock is trading +4.5% above its intraday low and -1.0% below the session's peak.

Trading activity shows a volume of 900.13K, compared to an average daily volume of 735K.

Over the past 52 weeks, Regeneron(REGN) stock has traded between a high of $821.11 and a low of $541.00.

REGN News

TipRanks 7h

Regeneron Pharmaceuticals Lawsuit Alleges Investors Were Misled Before REGN Stock Drops

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing a federal securities lawsuit alleging that investors were not fully informed about risks tied to a Phas...

Seeking Alpha 8h

Kiniksa tops Q2 estimates on Regeneron-partnered Arcalyst

Kiniksa Pharmaceuticals (KNSA) added nearly 50% on Tuesday after posting another quarterly beat and guidance boost with its financials, thanks mainly to Arcalys...

MarketWatch 1d

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

...

Analyst ratings

67%

of 30 ratings

Buy

66.7%

Hold

33.3%

Sell

More REGN News

Simply Wall St 2d

Telix-Regeneron Radiopharma Deal and Lawsuit Could Be A Game Changer For Regeneron Pharmaceuticals

In July 2026, Telix Pharmaceuticals announced it had entered a collaboration with Regeneron Pharmaceuticals to co-develop and commercialize next-generation radi...

Simply Wall St 6d

Regeneron Pharmaceuticals Could Be 19% Undervalued After Recent Pipeline Focus

Advertisement Event overview and why Regeneron Pharmaceuticals stock is in focus Regeneron Pharmaceuticals (REGN) is back in the spotlight after a new collabo...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.